<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 15, 2026 at 9:17 pm by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://theregenreport.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Regen Report</title>
		<link><![CDATA[https://theregenreport.com]]></link>
		<description><![CDATA[Regen Report]]></description>
		<lastBuildDate><![CDATA[Sun, 15 Nov 2026 17:59:19 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://theregenreport.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/15/tempo-therapeutics-receives-nih-grant-of-up-to-2-25-million-to-study-synthetic-wound-matrix/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/15/tempo-therapeutics-receives-nih-grant-of-up-to-2-25-million-to-study-synthetic-wound-matrix/]]></link>
			<title>Tempo Therapeutics Receives NIH Grant of Up to $2.25 Million to Study Synthetic Wound Matrix</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 17:59:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/15/university-of-alberta-launches-regenerative-medicine-hub-to-advance-research-and-commercialization/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/15/university-of-alberta-launches-regenerative-medicine-hub-to-advance-research-and-commercialization/]]></link>
			<title>University of Alberta Launches Regenerative Medicine Hub to Advance Research and Commercialization</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 17:55:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/15/gsk-to-acquire-trispecific-t-cell-engager-for-multiple-myeloma-from-chimagen-in-deal-worth-up-to-750-million/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/15/gsk-to-acquire-trispecific-t-cell-engager-for-multiple-myeloma-from-chimagen-in-deal-worth-up-to-750-million/]]></link>
			<title>GSK to Acquire Trispecific T Cell Engager for Multiple Myeloma From Chimagen in Deal Worth Up to $750 Million</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 17:51:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/15/university-hospital-tuebingens-new-trial-tests-cd19-car-t-cell-therapy-for-autoimmune-diseases/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/15/university-hospital-tuebingens-new-trial-tests-cd19-car-t-cell-therapy-for-autoimmune-diseases/]]></link>
			<title>University Hospital Tuebingen’s New Trial Tests CD19 CAR T-Cell Therapy for Autoimmune Diseases</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 16:08:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/14/shanghai-jiao-tong-university-school-of-medicine-tests-intranasal-umbilical-cord-exosomes-for-early-parkinsons-disease/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/14/shanghai-jiao-tong-university-school-of-medicine-tests-intranasal-umbilical-cord-exosomes-for-early-parkinsons-disease/]]></link>
			<title>Shanghai Jiao Tong University School of Medicine Tests Intranasal Umbilical Cord Exosomes for Early Parkinson’s Disease</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 03:41:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/14/personalized-stem-cells-new-trial-tests-adipose-stem-cell-therapy-for-chronic-mild-traumatic-brain-injury/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/14/personalized-stem-cells-new-trial-tests-adipose-stem-cell-therapy-for-chronic-mild-traumatic-brain-injury/]]></link>
			<title>Personalized Stem Cells’ New Trial Tests Adipose Stem Cell Therapy for Chronic Mild Traumatic Brain Injury</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 00:45:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/14/royan-stem-cell-technologys-new-trial-tests-mesenchymal-stromal-cells-for-stroke/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/14/royan-stem-cell-technologys-new-trial-tests-mesenchymal-stromal-cells-for-stroke/]]></link>
			<title>Royan Stem Cell Technology’s New Trial Tests Mesenchymal Stromal Cells for Stroke</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 00:45:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/14/anhui-hygeiancells-biomedical-tests-a-cell-free-embryo-extract-for-knee-osteoarthritis/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/14/anhui-hygeiancells-biomedical-tests-a-cell-free-embryo-extract-for-knee-osteoarthritis/]]></link>
			<title>Anhui HygeianCells BioMedical Tests a Cell-Free Embryo Extract for Knee Osteoarthritis</title>
			<pubDate><![CDATA[Sun, 15 Nov 2026 00:22:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/14/ori-biotech-nabs-120-million-contract-to-integrate-its-automated-cell-therapy-manufacturing-platform/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/14/ori-biotech-nabs-120-million-contract-to-integrate-its-automated-cell-therapy-manufacturing-platform/]]></link>
			<title>Ori Biotech Nabs $120 Million Contract to Integrate Its Automated Cell Therapy Manufacturing Platform</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 19:40:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/14/tikva-allocell-presents-preclinical-findings-on-armored-allogeneic-cd19-car-t-cell-therapy-for-systemic-lupus-erythematosus/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/14/tikva-allocell-presents-preclinical-findings-on-armored-allogeneic-cd19-car-t-cell-therapy-for-systemic-lupus-erythematosus/]]></link>
			<title>Tikva Allocell Presents Preclinical Findings on Armored Allogeneic CD19 CAR T-Cell Therapy for Systemic Lupus Erythematosus</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 19:36:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/14/shennon-biotechnologies-raises-12-million-unveils-t-cell-oncology-pipeline/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/14/shennon-biotechnologies-raises-12-million-unveils-t-cell-oncology-pipeline/]]></link>
			<title>Shennon Biotechnologies Raises $12 Million, Unveils T-Cell Oncology Pipeline</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 19:11:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/13/california-agency-awards-9-million-to-enloe-health-for-northern-california-regenerative-medicine-access-center/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/13/california-agency-awards-9-million-to-enloe-health-for-northern-california-regenerative-medicine-access-center/]]></link>
			<title>California Agency Awards $9 Million to Enloe Health for Northern California Regenerative Medicine Access Center</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 04:23:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/13/uconn-health-launches-car-t-cell-therapy-program-for-blood-cancers/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/13/uconn-health-launches-car-t-cell-therapy-program-for-blood-cancers/]]></link>
			<title>UConn Health Launches CAR-T Cell Therapy Program for Blood Cancers</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 03:54:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/13/iregene-therapeutics-allogeneic-photoreceptor-cell-therapy-cleared-by-u-s-and-chinese-regulators-for-retinitis-pigmentosa-clinical-trials/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/13/iregene-therapeutics-allogeneic-photoreceptor-cell-therapy-cleared-by-u-s-and-chinese-regulators-for-retinitis-pigmentosa-clinical-trials/]]></link>
			<title>iRegene Therapeutics’ Allogeneic Photoreceptor Cell Therapy Cleared by U.S. and Chinese Regulators for Retinitis Pigmentosa Clinical Trials</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 03:51:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/13/promega-licenses-reporter-technologies-to-brainxell-for-engineered-stem-cell-neural-models/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/13/promega-licenses-reporter-technologies-to-brainxell-for-engineered-stem-cell-neural-models/]]></link>
			<title>Promega Licenses Reporter Technologies to BrainXell for Engineered Stem Cell Neural Models</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 01:09:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/13/verigraft-partners-with-bramble-bio-on-gmp-manufacturing-for-personalised-tissue-engineered-vein/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/13/verigraft-partners-with-bramble-bio-on-gmp-manufacturing-for-personalised-tissue-engineered-vein/]]></link>
			<title>VERIGRAFT Partners with Bramble Bio on GMP Manufacturing for Personalised Tissue-Engineered Vein</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 00:26:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/13/kamau-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-gene-corrected-stem-cell-therapy-for-sickle-cell-disease/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/13/kamau-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-gene-corrected-stem-cell-therapy-for-sickle-cell-disease/]]></link>
			<title>Kamau Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Gene-Corrected Stem Cell Therapy for Sickle Cell Disease</title>
			<pubDate><![CDATA[Sat, 14 Nov 2026 00:06:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/13/thewell-bioscience-launches-animal-origin-free-rocketcell-supplements-for-stem-cell-and-organoid-culture/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/13/thewell-bioscience-launches-animal-origin-free-rocketcell-supplements-for-stem-cell-and-organoid-culture/]]></link>
			<title>TheWell Bioscience Launches Animal Origin-Free RocketCell Supplements for Stem Cell and Organoid Culture</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 05:20:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/12/ncardia-adds-six-human-induced-pluripotent-stem-cell-derived-neuronal-models-for-cns-research/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/12/ncardia-adds-six-human-induced-pluripotent-stem-cell-derived-neuronal-models-for-cns-research/]]></link>
			<title>Ncardia Adds Six Human Induced Pluripotent Stem Cell-Derived Neuronal Models for CNS Research</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:53:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/12/kangstem-biotech-reports-positive-phase-2a-results-for-stem-cell-knee-osteoarthritis-therapy/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/12/kangstem-biotech-reports-positive-phase-2a-results-for-stem-cell-knee-osteoarthritis-therapy/]]></link>
			<title>Kangstem Biotech Reports Positive Phase 2a Results for Stem Cell Knee Osteoarthritis Therapy</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 04:44:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/12/konkuk-university-team-reports-urine-derived-stem-cell-platform-restores-erectile-function-indicator-in-nerve-injured-rats/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/12/konkuk-university-team-reports-urine-derived-stem-cell-platform-restores-erectile-function-indicator-in-nerve-injured-rats/]]></link>
			<title>Konkuk University Team Reports Urine-Derived Stem Cell Platform Restores Erectile Function Indicator in Nerve-Injured Rats</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 01:02:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/12/restem-receives-fda-clearance-for-phase-1-2-trial-of-secretome-based-therapy-in-knee-osteoarthritis/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/12/restem-receives-fda-clearance-for-phase-1-2-trial-of-secretome-based-therapy-in-knee-osteoarthritis/]]></link>
			<title>RESTEM Receives FDA Clearance for Phase 1/2 Trial of Secretome-Based Therapy in Knee Osteoarthritis</title>
			<pubDate><![CDATA[Fri, 13 Nov 2026 00:57:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/stay-updated/]]></guid>
			<link><![CDATA[https://theregenreport.com/stay-updated/]]></link>
			<title>Stay Updated</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 21:39:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/laxco-introduces-celllive-series-for-continuous-live-cell-imaging-inside-standard-incubators/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/laxco-introduces-celllive-series-for-continuous-live-cell-imaging-inside-standard-incubators/]]></link>
			<title>Laxco Introduces CellLive Series for Continuous Live-Cell Imaging Inside Standard Incubators</title>
			<pubDate><![CDATA[Thu, 12 Nov 2026 17:11:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/maxcyte-to-acquire-cell-therapy-reagent-supplier-akron-bio-for-151-8-million/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/maxcyte-to-acquire-cell-therapy-reagent-supplier-akron-bio-for-151-8-million/]]></link>
			<title>MaxCyte to Acquire Cell Therapy Reagent Supplier Akron Bio for $151.8 Million</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 21:53:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/brainxell-and-neuroservices-alliance-profile-induced-pluripotent-stem-cell-derived-sensory-neurons/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/brainxell-and-neuroservices-alliance-profile-induced-pluripotent-stem-cell-derived-sensory-neurons/]]></link>
			<title>BrainXell and Neuroservices-Alliance Profile Induced Pluripotent Stem Cell–Derived Sensory Neurons</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 20:36:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/california-institute-for-regenerative-medicine-awards-6-9-million-for-preclinical-development-of-stem-cell-derived-cardiac-muscle-therapy-for-severe-heart-attack/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/california-institute-for-regenerative-medicine-awards-6-9-million-for-preclinical-development-of-stem-cell-derived-cardiac-muscle-therapy-for-severe-heart-attack/]]></link>
			<title>California Institute for Regenerative Medicine Awards $6.9 Million for Preclinical Development of Stem Cell-Derived Cardiac Muscle Therapy for Severe Heart Attack</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 19:44:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/casebioscience-joins-likarda-led-team-awarded-up-to-7-3-million-to-develop-ambient-preservation-of-cell-therapies/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/casebioscience-joins-likarda-led-team-awarded-up-to-7-3-million-to-develop-ambient-preservation-of-cell-therapies/]]></link>
			<title>CaseBioscience Joins Likarda-Led Team Awarded Up to $7.3 Million to Develop Ambient Preservation of Cell Therapies</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 18:55:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/corestemchemon-launches-u-s-subsidiary-in-winston-salem-to-commercialize-stem-cell-therapy-for-als/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/corestemchemon-launches-u-s-subsidiary-in-winston-salem-to-commercialize-stem-cell-therapy-for-als/]]></link>
			<title>CorestemChemon Launches U.S. Subsidiary in Winston-Salem to Commercialize Stem Cell Therapy for ALS</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 18:40:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/ocugen-executes-licensing-agreement-for-exclusive-middle-east-and-north-africa-rights-to-modifier-gene-therapy-for-retinitis-pigmentosa/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/ocugen-executes-licensing-agreement-for-exclusive-middle-east-and-north-africa-rights-to-modifier-gene-therapy-for-retinitis-pigmentosa/]]></link>
			<title>Ocugen Executes Licensing Agreement for Exclusive Middle East and North Africa Rights to Modifier Gene Therapy for Retinitis Pigmentosa</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 17:42:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/reprocell-launches-bioengineered-full-thickness-human-skin-model/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/reprocell-launches-bioengineered-full-thickness-human-skin-model/]]></link>
			<title>REPROCELL Launches Bioengineered Full-Thickness Human Skin Model</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 16:54:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/cellfiber-opens-first-international-subsidiary-in-philadelphia-to-support-cell-and-gene-therapy-development/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/cellfiber-opens-first-international-subsidiary-in-philadelphia-to-support-cell-and-gene-therapy-development/]]></link>
			<title>CellFiber Opens First International Subsidiary in Philadelphia to Support Cell and Gene Therapy Development</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 16:48:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/tissium-earns-ce-mark-for-non-penetrating-ventral-hernia-mesh-fixation-device/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/tissium-earns-ce-mark-for-non-penetrating-ventral-hernia-mesh-fixation-device/]]></link>
			<title>TISSIUM Earns CE Mark for Non-Penetrating Ventral Hernia Mesh Fixation Device</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 05:22:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/11/curi-bio-expands-curiverse-3d-tissue-ecosystem-with-new-disease-models-casting-kits-and-assay-services/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/11/curi-bio-expands-curiverse-3d-tissue-ecosystem-with-new-disease-models-casting-kits-and-assay-services/]]></link>
			<title>Curi Bio Expands Curiverse 3D Tissue Ecosystem with New Disease Models, Casting Kits, and Assay Services</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 05:18:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/cellbox-solutions-closes-eur-5-million-series-a-to-expand-warm-chain-logistics-for-cells-and-tissues/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/cellbox-solutions-closes-eur-5-million-series-a-to-expand-warm-chain-logistics-for-cells-and-tissues/]]></link>
			<title>Cellbox Solutions Closes EUR 5 Million Series A to Expand Warm-Chain Logistics for Cells and Tissues</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:50:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/fibrobiologics-receives-australian-patent-acceptance-for-cellular-blend-to-regenerate-cartilage-in-degenerated-spinal-discs/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/fibrobiologics-receives-australian-patent-acceptance-for-cellular-blend-to-regenerate-cartilage-in-degenerated-spinal-discs/]]></link>
			<title>FibroBiologics Receives Australian Patent Acceptance for Cellular Blend to Regenerate Cartilage in Degenerated Spinal Discs</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:43:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/rznomics-rna-editing-gene-therapy-receives-eu-orphan-designation-for-glioma/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/rznomics-rna-editing-gene-therapy-receives-eu-orphan-designation-for-glioma/]]></link>
			<title>Rznomics&#8217; RNA-Editing Gene Therapy Receives EU Orphan Designation for Glioma</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:10:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/evia-bio-announces-availability-of-gmp-grade-dmso-free-cryopreservation-media-for-mesenchymal-stromal-cells/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/evia-bio-announces-availability-of-gmp-grade-dmso-free-cryopreservation-media-for-mesenchymal-stromal-cells/]]></link>
			<title>Evia Bio Announces Availability of GMP-Grade DMSO-Free Cryopreservation Media for Mesenchymal Stromal Cells</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:06:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/immunebridge-partners-with-bloodworks-bio-to-use-public-cord-blood-for-allogeneic-cell-therapy-development/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/immunebridge-partners-with-bloodworks-bio-to-use-public-cord-blood-for-allogeneic-cell-therapy-development/]]></link>
			<title>ImmuneBridge Partners with Bloodworks Bio to Use Public Cord Blood for Allogeneic Cell Therapy Development</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 04:06:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/exogenus-therapeutics-leads-e13m-consortium-to-advance-umbilical-cord-blood-secretome-therapy-for-osteoarthritis/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/exogenus-therapeutics-leads-e13m-consortium-to-advance-umbilical-cord-blood-secretome-therapy-for-osteoarthritis/]]></link>
			<title>Exogenus Therapeutics Leads €13M Consortium to Advance Umbilical Cord Blood Secretome Therapy for Osteoarthritis</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 03:58:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/biocardia-completes-japan-regulatory-consultations-for-its-catheter-based-cardiac-cell-therapy-for-ischemic-heart-failure/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/biocardia-completes-japan-regulatory-consultations-for-its-catheter-based-cardiac-cell-therapy-for-ischemic-heart-failure/]]></link>
			<title>BioCardia Completes Japan Regulatory Consultations for Its Catheter-Based Cardiac Cell Therapy for Ischemic Heart Failure</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 02:28:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/porton-advanced-announces-fda-acceptance-of-drug-master-file-for-umbilical-cord-stem-cell-derived-exosomes/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/porton-advanced-announces-fda-acceptance-of-drug-master-file-for-umbilical-cord-stem-cell-derived-exosomes/]]></link>
			<title>Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 02:26:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/bristol-myers-squibb-reports-interim-phase-1-results-for-cd19-directed-car-t-cell-therapy-in-multiple-sclerosis/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/bristol-myers-squibb-reports-interim-phase-1-results-for-cd19-directed-car-t-cell-therapy-in-multiple-sclerosis/]]></link>
			<title>Bristol Myers Squibb Reports Interim Phase 1 Results for CD19-Directed CAR T Cell Therapy in Multiple Sclerosis</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 01:57:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/zymeworks-licenses-trispecific-t-cell-engager-targeting-dll3-to-roche/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/zymeworks-licenses-trispecific-t-cell-engager-targeting-dll3-to-roche/]]></link>
			<title>Zymeworks Licenses Trispecific T Cell Engager Targeting DLL3 to Roche</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 01:34:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/abelzeta-receives-fda-rmat-and-fast-track-designations-for-anti-cd20-cd19-bispecific-car-t-therapy-in-relapsed-or-refractory-large-b-cell-lymphoma/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/abelzeta-receives-fda-rmat-and-fast-track-designations-for-anti-cd20-cd19-bispecific-car-t-therapy-in-relapsed-or-refractory-large-b-cell-lymphoma/]]></link>
			<title>AbelZeta Receives FDA RMAT and Fast Track Designations for Anti-CD20/CD19 Bispecific CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 00:39:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/capricor-therapeutics-cardiosphere-derived-cell-therapy-trial-abstract-wins-cardiology-award/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/capricor-therapeutics-cardiosphere-derived-cell-therapy-trial-abstract-wins-cardiology-award/]]></link>
			<title>Capricor Therapeutics’ Cardiosphere-Derived Cell Therapy Trial Abstract Wins Cardiology Award</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 00:38:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/creative-medical-technology-holdings-reports-93-response-rate-in-six-month-pilot-study-of-investigational-ultrasome-for-knee-osteoarthritis/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/creative-medical-technology-holdings-reports-93-response-rate-in-six-month-pilot-study-of-investigational-ultrasome-for-knee-osteoarthritis/]]></link>
			<title>Creative Medical Technology Holdings Reports 93% Response Rate in Six-Month Pilot Study of Investigational Ultrasome for Knee Osteoarthritis</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 00:30:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/cellares-and-seoul-national-university-hospital-to-test-automated-manufacturing-for-a-gene-modified-blood-stem-cell-therapy/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/cellares-and-seoul-national-university-hospital-to-test-automated-manufacturing-for-a-gene-modified-blood-stem-cell-therapy/]]></link>
			<title>Cellares and Seoul National University Hospital to Test Automated Manufacturing for a Gene-Modified Blood Stem Cell Therapy</title>
			<pubDate><![CDATA[Wed, 11 Nov 2026 00:25:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/2026/11/10/matricelf-receives-fda-feedback-supporting-proposed-first-in-human-trial-design-for-newral-in-traumatic-spinal-cord-injury/]]></guid>
			<link><![CDATA[https://theregenreport.com/2026/11/10/matricelf-receives-fda-feedback-supporting-proposed-first-in-human-trial-design-for-newral-in-traumatic-spinal-cord-injury/]]></link>
			<title>Matricelf Receives FDA Feedback Supporting Proposed First-in-Human Trial Design for NewRal in Traumatic Spinal Cord Injury</title>
			<pubDate><![CDATA[Tue, 10 Nov 2026 23:44:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://theregenreport.com/]]></guid>
			<link><![CDATA[https://theregenreport.com/]]></link>
			<title>Homepage</title>
			<pubDate><![CDATA[Wed, 25 Feb 2026 22:57:30 +0000]]></pubDate>
		</item>
				</channel>
</rss>
